- €13.00bn
- €12.43bn
- €3.93bn
France rejects Trump's comment on drug prices, calls it 'fake news'
Brief: IPSEN: Arbitration Tribunal Upholds Ipsen's Termination Of Research And Development Agreement With Galderma
Brief: Ipsen Says 45.7% Spasticity Rate In Stroke Survivors In EPITOME Trial
Brief: Ipsen Says U.S. FDA Grants Ipsen’s IPN60340 Breakthrough Therapy Designation in first line unfit Acute Myeloid Leukemia
Europe Research Roundup: BNP Paribas, Swedbank, Volkswagen
Top of the Street: Ipsen, Carnival, consumer goods, REITs, oil
UBS cuts Ipsen to 'neutral' as Cabometyx patent cliff looms
Brief: Ipsen Gains Global Rights For Development, Manufacturing Of SIM0613
Ipsen shares fall after failed trial on experimental FOP drug
Brief: Ipsen: Phase II Falkon Trial Did Not Meet Primary Endpoint
Brief: Ipsen Completes Acquisition Of Imcheck Therapeutics
Brief: Ipsen: Beech Tree Shares To Be Transferred To Alasol Foundation
BNP Paribas Exane downgrades Ipsen to 'underperform' amid competitive pressures
Europe Research Roundup: Adidas, Boliden, LSEG
Brief: Eqt Life Sciences' Imcheck Therapeutics To Be Acquired By Ipsen
Ipsen rises after Q3 beat, outlook hike
Brief: Gimv Sells Imcheck Therapeutics Stake To Ipsen For EUR 350 Mln
Brief: Ipsen To Acquire Imcheck Therapeutics
Brief: Ipsen Q3 Revenue EUR 915 Million, Upgrades 2025 Outlook